A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis

被引：17

作者：

Johnson, M. L. ^{[1
]}

Gort, E. ^{[2
]}

Pant, S. ^{[3
]}

Lolkema, M. P. ^{[4
]}

Sebastian, M. ^{[5
,6
]}

Scheffler, M.

Hwang, J. ^{[7
]}

Duenzinger, U. ^{[8
]}

Riemann, K. ^{[9
]}

Kitzing, T. ^{[10
]}

Janne, P. A. ^{[11
]}

机构：

[1] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[2] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands

[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

[4] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands

[5] Univ Hosp, Dept Hematol & Oncol, Frankfurt, Germany

[6] Univ Hosp Cologne, Ctr Integrated Oncol Cologne, Dept Internal Med, Cologne, Germany

[7] Levine Canc Inst, Dept Oncol, Charlotte, NC USA

[8] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany

[9] Boehringer Ingelheim Pharma GmbH & Co KG, Global Clin Operat, Biberach, Germany

[10] Boehringer Ingelheim Pharma GmbH & Co KG, Translat Med & Clin Pharmacol, Biberach, Germany

[11] Lowe Ctr Thorac Oncol, Dana Farber Canc Inst, Boston, MA USA

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.1046

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

524P

引用

页码：S591 / S592

页数：2